Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Roberto Carmagnani Pestana"'
Autor:
Roberto Carmagnani Pestana, Bruna Bianca Lopes David, Veridiana Pires de Camargo, Rodrigo Ramella Munhoz, Celso Abdon Lopes de Mello, María Lucila González Donna, Juan Carlos Haro Varas, Maycos L. Zapata, Cicero Luiz Cunha Martins, Matias Chacon, Rafael Schmerling, Reynaldo Jesus-Garcia
Publikováno v:
The Lancet Regional Health. Americas, Vol 30, Iss , Pp 100671- (2024)
Summary: As a developing region, Latin America faces unique cancer control and prevention challenges, which are intensified when considering rare cancers, including sarcomas. Sarcomas are a group of malignancies that arise in the connective tissues o
Externí odkaz:
https://doaj.org/article/178b83fb808d41e5931f0e2ad913e0c4
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundThe development of novel therapies for patients with sarcoma is challenging due to the rarity and diversity of these mesenchymal neoplasms. Hence, histology-agnostic approvals can be of particular interest for the treatment of patients with
Externí odkaz:
https://doaj.org/article/7bbdbba71afb40c185bfae04036fc717
Autor:
Ahmed O. Kaseb, Abedul Haque, Deeksha Vishwamitra, Manal M. Hassan, Lianchun Xiao, Bhawana George, Vishal Sahu, Yehia I. Mohamed, Roberto Carmagnani Pestana, Jamie Lynne Lombardo, Rony Avritscher, James C. Yao, Robert A. Wolff, Asif Rashid, Jeffrey S. Morris, Hesham M. Amin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. There
Externí odkaz:
https://doaj.org/article/224741d9023048d79f5c82c97fdcee84
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Although a relatively uncommon tumor, cholangiocarcinoma is on the rise globally. Of note, most patients are diagnosed with metastatic disease, and the prognosis is poor with cytotoxic chemotherapy. Strategies targeting specific genomic alterations h
Externí odkaz:
https://doaj.org/article/afdb45f407fa441e88f2e902abed75eb
Autor:
Aliya Qayyum, Ken-Pin Hwang, Jason Stafford, Anuj Verma, Dipen M. Maru, Subramanya Sandesh, Jia Sun, Roberto Carmagnani Pestana, Rony Avritscher, Manal M. Hassan, Hesham Amin, Asif Rashid, Ignacio I. Wistuba, Richard L. Ehman, Jingfei Ma, Ahmed O. Kaseb
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Abstract Background Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of imm
Externí odkaz:
https://doaj.org/article/73309b6a517145a2968535497c6f6d9f
Autor:
Jenifer Loureiro, Gian Luigi Menegazzo, Lucas Vergamini, Roberto Carmagnani Pestana, Fernanda Bellotti Formiga, Marcella Guilherme Carolino de Sousa, Thais Yuka Takahashi, Felipe Silveira, Paulo de Azeredo Passos Candelária, Dino Martini Filho, Fang Chia Bin
Publikováno v:
Journal of Coloproctology, Vol 35, Iss 1, Pp 67-71 (2015)
A case of diagnostic difficulty facing the patient with colonic polyposis secondary to Peutz–Jeghers syndrome, but without family history and pathognomonic clinical features of the disease, is illustrated. The exams, including biopsy, led to diagno
Externí odkaz:
https://doaj.org/article/96cb51408b10412786371091ddd91fc9
Autor:
Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
Clinical Cancer Research. 29:1708-1718
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78f23ea3e8e64341e0552b9d54de1861
https://doi.org/10.1158/1078-0432.ccr-22-3629
https://doi.org/10.1158/1078-0432.ccr-22-3629
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff57d97d02e8e004b84f0db0adb9a0a
https://doi.org/10.1158/1078-0432.22634420.v1
https://doi.org/10.1158/1078-0432.22634420.v1
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Purpose:Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44b2bbce2946a303e6ad0c658b3cbb82
https://doi.org/10.1158/1078-0432.c.6600059.v1
https://doi.org/10.1158/1078-0432.c.6600059.v1
Autor:
Vivek Subbiah, Funda Meric-Bernstam, Richard Gorlick, Nelson Hamerschlak, Anthony P. Conley, Joseph A. Ludwig, Neeta Somaiah, J. Andrew Livingston, Shreyaskumar R. Patel, Christina L. Roland, Valerae O. Lewis, Douglas J. Harrison, Jonathan B. Gill, Najat Daw, Wei-Lien Wang, Alexander J. Lazar, Robert S. Benjamin, Vinod Ravi, Ravin Ratan, Maria A. Zarzour, Shubham Pant, Apostolia M. Tsimberidou, Daniel D. Karp, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Siqing Fu, Cynthia E. Herzog, Aung Naing, David S. Hong, Shiraj Sen, Jason Roszik, Justin T. Moyers, Roberto Carmagnani Pestana
Summary of response outcomes across subgroups
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7f75586d0c115b6f39ae8a9adfd5e4
https://doi.org/10.1158/1078-0432.22634417
https://doi.org/10.1158/1078-0432.22634417